Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated
platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk …

Immune thrombocytopenia (ITP) is an autoimmune disease affecting blood platelets that
causes thrombocytopenia and an increased risk of bleeding. First-line therapy is indicated …

Autoimmune cytopenias include autoimmune hemolytic anemia (AIHA), immune
thrombocytopenia (ITP), and autoimmune neutropenia (AIN), as well as rarer multilineage …

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated
thrombocytopenia and hemorrhagic risk. While many children with ITP can be safely …

Immune thrombocytopenia (ITP), an acquired autoimmune disorder of low platelets and risk
of bleeding, has a substantial impact on health‐related quality of life (HRQoL). Patients with …

Immune thrombocytopenia (ITP) is a disease of heterogenous origin characterized by low
platelet counts and an increased bleeding tendency. Three disease phases have been …

Background Children with immune thrombocytopenia (ITP) may require second‐line ITP
therapies. The high remission rate in pediatric patients, need for extended‐duration use of …

The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors used
to treat immune thrombocytopenia (ITP) in children and adults. Romiplostim is a peptide …

Introduction Immune thrombocytopenia (ITP) is an autoimmune disorder caused by
immunologic destruction of otherwise normal platelets. Patients and physicians differ in their …

Immune thrombocytopenia (ITP) is the most common bleeding disorder diagnosed in
children. Characterized by low platelet counts, it leads to reduced clotting abilities and an …